InvestSMART

Clinuvel Pharmaceuticals Limited (ASX: CUV) - Announcements

Current share price for CUV : $8.370 0.21 (2.57%)+

ASX company news and announcements for Clinuvel Pharmaceuticals Limited (CUV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clinuvel Pharmaceuticals Limited (CUV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clinuvel Pharmaceuticals Limited (CUV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clinuvel Pharmaceuticals Limited (CUV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$422 CLINUVEL Unveils Vitiligo Program for AAD 2025 4 Mar 2025 8:59AM $12.230 $8.370 fallen by 31.56%
$422 CLINUVEL Investor Webinar 28 Feb 2025 9:06AM $11.750 $8.370 fallen by 28.77%
$422 Chair Letter to Shareholders 28 Feb 2025 9:04AM $11.750 $8.370 fallen by 28.77%
$422 Half Year Results Presentation 27 Feb 2025 10:48AM $11.670 $8.370 fallen by 28.28%
$422 Half Year Results Announcement 27 Feb 2025 10:47AM $11.670 $8.370 fallen by 28.28%
$422 Appendix 4D and Half Year Report 27 Feb 2025 10:42AM $11.670 $8.370 fallen by 28.28%
$422 CLINUVEL Investor Webinar 20 Feb 2025 9:05AM $11.120 $8.370 fallen by 24.73%
$422 Change in substantial holding 17 Feb 2025 8:20AM $11.400 $8.370 fallen by 26.58%
$422 Preliminary results from SCENESSE adolescent EPP study 10 Feb 2025 9:05AM $11.470 $8.370 fallen by 27.03%
$422 Vitiligo - CUV105 Study Update 20 Jan 2025 9:39AM $11.880 $8.370 fallen by 29.55%
$422 SCENESSE Argentinian distribution agreement 17 Jan 2025 9:22AM $11.790 $8.370 fallen by 29.01%
$422 Managing Director Letter to Shareholders 23 Dec 2024 9:18AM $11.790 $8.370 fallen by 29.01%
$422 Health Canada validates SCENESSE New Drug Submission 23 Dec 2024 9:16AM $11.790 $8.370 fallen by 29.01%
$422 Revised Securities Trading Policy 18 Dec 2024 4:11PM $12.000 $8.370 fallen by 30.25%
$422 Becoming a substantial holder 6 Dec 2024 8:21AM $13.100 $8.370 fallen by 36.11%
$422 Chair's letter to Shareholders 5 Dec 2024 9:06AM $12.960 $8.370 fallen by 35.42%
$422 Notification of cessation of securities - CUV 4 Dec 2024 9:19AM $12.960 $8.370 fallen by 35.42%
$422 SCENESSE dosage expansion under review by EMA 20 Nov 2024 9:13AM $13.620 $8.370 fallen by 38.55%
$422 CLINUVEL Bell Potter Healthcare Conference Presentation 18 Nov 2024 8:52AM $13.280 $8.370 fallen by 36.97%
$422 CLINUVEL prioritises three strategic programs 18 Nov 2024 8:46AM $13.280 $8.370 fallen by 36.97%
$422 Final Director's Interest Notice - Brenda Shanahan 17 Oct 2024 9:20AM $14.110 $8.370 fallen by 40.68%
$422 Results of Meeting 16 Oct 2024 1:44PM $14.350 $8.370 fallen by 41.67%
$422 Managing Director Presentation 16 Oct 2024 9:14AM $14.500 $8.370 fallen by 42.28%
$422 Chair's Address 16 Oct 2024 9:13AM $14.500 $8.370 fallen by 42.28%
$422 Appendix 3Y - Karen Agersborg 3 Oct 2024 4:40PM $13.990 $8.370 fallen by 40.17%

101 - 125 of 872 results

Page 5 of 35

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.